Neuropace Inc (NPCE)
NeuroPace, Inc. is a U.S.-based medical device company focused on treatments for drug-resistant focal epilepsy. Its core offering is the RNS System, a brain-responsive neuromodulation platform designed to deliver personalized, real-time therapy at the seizure source. The system includes the RNS neurostimulator, cortical strip and depth leads, a Patient Remote Monitor, and related implantable and non-implantable accessories. The company also provides a physician tablet for device programming and patient management, a secure patient data management system, and the nSight Platform, which generates patient reports and programming guidance for clinicians. NeuroPace sells its products to hospital facilities for both initial implant procedures and replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NPCE
|
$9.58
|
-39.0% Downside
|
Overvalued
|
$20
|
27.3% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-24.9x
|
37.1x
|
5.4x
|
537 M
|
552.8 M
|
11.6%
|
68.3%
|
-2.8
|
—
|
45.6%
|
